Study to Evaluate the Pharmacokinetics (movement of drugs within the body), Safety and Tolerability of Brazikumab in Healthy Chinese and White Participants

Trial Identifier: D5271C00004
Sponsor: AstraZeneca
NCTID:: NCT05033431
Start Date: October 2021
Primary Completion Date: October 2022
Study Completion Date: October 2022

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Chinese (Simplified) Translation
Chinese (Traditional) Translation

Trial Locations

Country Location
US, CA Glendale, CA, US, 91206